176 related articles for article (PubMed ID: 35172312)
1. Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients.
Shashar M; Nacasch N; Grupper A; Benchetrit S; Halperin T; Erez D; Rozenberg I; Shitrit P; Sela Y; Wand O; Cohen-Hagai K
Am J Nephrol; 2022; 53(2-3):207-214. PubMed ID: 35172312
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
3. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
Casas Fischer R
Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
[TBL] [Abstract][Full Text] [Related]
4. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
5. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.
Grupper A; Sharon N; Finn T; Cohen R; Israel M; Agbaria A; Rechavi Y; Schwartz IF; Schwartz D; Lellouch Y; Shashar M
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1037-1042. PubMed ID: 33824157
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis.
Bensouna I; Caudwell V; Kubab S; Acquaviva S; Pardon A; Vittoz N; Bozman DF; Hanafi L; Faucon AL; Housset P
Am J Kidney Dis; 2022 Feb; 79(2):185-192.e1. PubMed ID: 34508833
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
8. The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose.
Cohen I; Campisi-Pfinto S; Rozenberg O; Colodner R; Bar-Sela G
Oncologist; 2023 Apr; 28(4):e225-e227. PubMed ID: 36856804
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of the BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis Is Associated with Medical Conditions.
Guinault D; Bernier M; Delarche A; Neuville S; Milioto O; Molinari N; Dahan P
Nephron; 2022; 146(6):553-558. PubMed ID: 35477156
[TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients.
De Cagna MR; Colucci V; Di Maggio A; Notaristefano N; Cianciotta F; Danza K; Salvatore F; Santoniccolo A; Lanzillotta SG; Perniola MA; Marangi AL; Morrone LFP; Tampoia M
Clin Exp Nephrol; 2023 May; 27(5):445-453. PubMed ID: 36795176
[TBL] [Abstract][Full Text] [Related]
11. Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study.
Mirioglu S; Kazancioglu R; Cebeci E; Eren N; Sakaci T; Alagoz S; Tugcu M; Tuglular S; Sumbul B; Seyahi N; Ozturk S
Nephron; 2023; 147(7):392-400. PubMed ID: 36603567
[TBL] [Abstract][Full Text] [Related]
12. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
13. Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients.
Einbinder Y; Perl J; Nacasch N; Bnaya A; Shavit L; Erez D; Shashar M; Halperin T; Grupper A; Benchetrit S; Wand O; Cohen-Hagai K
Am J Nephrol; 2022; 53(7):586-590. PubMed ID: 35850101
[TBL] [Abstract][Full Text] [Related]
14. A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis.
Espi M; Charmetant X; Barba T; Mathieu C; Pelletier C; Koppe L; Chalencon E; Kalbacher E; Mathias V; Ovize A; Cart-Tanneur E; Bouz C; Pellegrina L; Morelon E; Juillard L; Fouque D; Couchoud C; Thaunat O;
Kidney Int; 2022 Feb; 101(2):390-402. PubMed ID: 34856313
[TBL] [Abstract][Full Text] [Related]
15. Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components.
Busà R; Sorrentino MC; Russelli G; Amico G; Miceli V; Miele M; Di Bella M; Timoneri F; Gallo A; Zito G; Di Carlo D; Conaldi PG; Bulati M
Front Immunol; 2022; 13():856657. PubMed ID: 35401503
[TBL] [Abstract][Full Text] [Related]
16. Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients.
Wand O; Nacasch N; Fadeela A; Shashar M; Grupper A; Benchetrit S; Erez D; Shitrit P; Cohen-Hagai K
J Nephrol; 2022 Jun; 35(5):1479-1487. PubMed ID: 35175577
[TBL] [Abstract][Full Text] [Related]
17. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
19. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
